Fluconazole
- Generic Name
- Fluconazole
- Brand Names
- Diflucan
- Drug Type
- Small Molecule
- Chemical Formula
- C13H12F2N6O
- CAS Number
- 86386-73-4
- Unique Ingredient Identifier
- 8VZV102JFY
- Background
Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole has many advantages over the other antifungal dr...
- Indication
Fluconazole can be administered in the treatment of the following fungal infections:
1) Vaginal yeast infections caused by Candida
2) Systemic Candida infections
3) Both esophageal and oropharyngeal candidiasis
4) Cryptococcal meningitis
5) UTI (urinary tract infection) by Candida
6) Peritonitis (inflammation of the peritoneum) caused by Candida
...
- Associated Conditions
- Candida intertrigo, Candida pneumonia, Candida urinary tract infection, Candidemia, Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Meningitis, Cryptococcal, Oropharyngeal Candidiasis, Peritoneal candidiasis, Pneumonia cryptococcal, Pruritus, Skin Irritation, Systemic Candida Infections caused by Candida, Vaginal Candidiasis, Disseminated Candidiasis
- Associated Therapies
- -
Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002074
- Locations
- 🇺🇸
Dr Richard Meyer, Los Angeles, California, United States
🇺🇸DeKalb Gen Hosp, Decatur, Georgia, United States
🇺🇸Shallowford Hosp, Decatur, Georgia, United States
A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 720
- Registration Number
- NCT00002122
- Locations
- 🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸UCSD Treatment Ctr / Dept of Medicine and Pediatrics, San Diego, California, United States
🇺🇸Univ of Massachusetts Med Ctr, Worcester, Massachusetts, United States
Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002076
- Locations
- 🇺🇸
Summitt Med Ctr / San Francisco Gen Hosp, Oakland, California, United States
🇺🇸Cornell Univ Med Ctr, New York, New York, United States
🇺🇸Buckley Braffman Stern Med Associates, Philadelphia, Pennsylvania, United States
A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002068
- Locations
- 🇺🇸
Christiana Hosp / Med Ctr of Delaware, Wilmington, Delaware, United States
🇺🇸Univ of Tennessee, Memphis, Tennessee, United States
🇺🇸Davies Med Ctr, San Francisco, California, United States
Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2010-08-27
- Target Recruit Count
- 500
- Registration Number
- NCT00001107
- Locations
- 🇺🇸
Mary Ellen Bradley, Birmingham, Alabama, United States
A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 24
- Registration Number
- NCT00000788
- Locations
- 🇺🇸
Addiction Research and Treatment Corp, Brooklyn, New York, United States
Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 330
- Registration Number
- NCT00001017
- Locations
- 🇺🇸
Beth Israel Deaconess - West Campus, Boston, Massachusetts, United States
🇺🇸SUNY - Stony Brook, Stony Brook, New York, United States
🇺🇸Duke Univ Med Ctr, Durham, North Carolina, United States
Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-14
- Target Recruit Count
- 120
- Registration Number
- NCT00000708
- Locations
- 🇺🇸
Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸Tulane Univ School of Medicine, New Orleans, Louisiana, United States
An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002077
- Locations
- 🇺🇸
Cook County Hosp, Chicago, Illinois, United States
🇺🇸Saint Michael's Med Ctr, Newark, New Jersey, United States
🇺🇸Cabrini Med Ctr, New York, New York, United States
A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 400
- Registration Number
- NCT00000744
- Locations
- 🇺🇸
Community Consortium of San Francisco, San Francisco, California, United States
🇺🇸AIDS Research Alliance - Chicago, Chicago, Illinois, United States
🇺🇸Denver CPCRA / Denver Public Hlth, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.